Treatment of acromegalic osteopathy in real-life clinical practice: The BAAC (bone active drugs in acromegaly) study
| Autor: | Carolina Di Somma, Silvia Grottoli, Andrea Lania, Emanuele Ferrante, Filippo Maffezzoni, Miriam Cellini, Iacopo Chiodini, Maura Arosio, Emanuela Morenghi, Laura De Marinis, Teresa Porcelli, Flavia Pugliese, Alberto Ferlin, Roberto Olivetti, Giulia Del Sindaco, Elisabetta Lavezzi, Alfredo Scillitani, Ludovica F S Grasso, Sabrina Chiloiro, Massimo Procopio, Antonio Bianchi, Rosario Pivonello, Marco Barale, Antonella Giampietro, Giovanna Mantovani, Federico Gatto, Nunzia Prencipe, Gherardo Mazziotti, Claudia Battista, Ezio Ghigo |
|---|---|
| Přispěvatelé: | Mazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L., Gatto, F., Olivetti, R., Arosio, M., Barale, M., Bianchi, A., Cellini, M., Chiodini, I., de Marinis, L., Sindaco, G. D., Somma, C. D., Ferlin, A., Ghigo, E., Giampietro, A., Grottoli, S., Lavezzi, E., Mantovani, G., Morenghi, E., Pivonello, R., Porcelli, T., Procopio, M., Pugliese, F., Scillitani, A., Lania, A. G. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Endocrinology Diabetes and Metabolism Clinical Biochemistry Osteoporosis Biochemistry 0302 clinical medicine Endocrinology Bone Density Teriparatide Longitudinal Studies Practice Patterns Physicians' Bone Density Conservation Agents Bisphosphonates Middle Aged Denosumab Italy 030220 oncology & carcinogenesis Vertebral fractures Spinal Fractures Female Bone Diseases medicine.drug Adult medicine.medical_specialty 030209 endocrinology & metabolism Acromegaly Bone-active drugs Lower risk 03 medical and health sciences Internal medicine Hypoadrenalism medicine Humans Bisphosphonate Aged Retrospective Studies business.industry Biochemistry (medical) Osteoporosi Settore MED/13 - ENDOCRINOLOGIA Odds ratio medicine.disease Osteopathy Bone-active drug business Complication |
| Popis: | Background Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and Methods Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P Conclusions Bone active drugs may prevent VFs in patients with active acromegaly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|